Teva Pharmaceutical Industries is like a skiff-racing team that's beating its own speed records on the river but heading for an enormous waterfall just around the bend. As well as it performs now, the question remains: How well can it recover from the imminent loss of Copaxone patent protection?
Big Pharma wants the U.S. to pull a big-gorilla act in India. With patents revoked and cheap generics foisted on them ahead of schedule--and more early copycats possibly on their way--multinational drugmakers are lobbying for an intervention.
Sanofi CEO Christopher Viehbacher finally got to say that this year, sales and earnings will grow. And the French drugmaker's fourth-quarter results--6.5% sales growth at constant exchange rates, and a reported 16.8% profits increase--allowed him to make that claim based on actual cash-based evidence.
AstraZeneca has upped its job-cutting toll to 5,600. After announcing 5,050 layoffs last year, the company disclosed today that it's adding another 550 to the mix. That brings the total workforce cuts to 5,600 jobs.
The story AstraZeneca is telling about its 2013 results is a familiar one: We've heard it from almost every Big Pharma since the patent cliff claimed its first megablockbuster victim. Generics are sapping our lifeblood, but don't worry, growth will come soon.
Most physicians use their tablets and smartphones at work, at home and everywhere in between. The question is how they use them.
France wants to save money on drugs. That's not unusual. It's proposing new plans to pump up use of generics. That's not unusual either. What's less common is that Bristol-Myers Squibb is threatening layoffs at two French factories in retaliation.
Given the thousands of pharma sales layoffs over the past several years--and recruiting focused on emerging markets, especially China--staffing up in the U.S. or Europe is out of the ordinary. Yet that's just what Novo Nordisk has been doing: hiring reps by the hundred in the U.S.
All the buzz about Gilead Sciences lately has been about hepatitis C. And no wonder: It has Sovaldi on its hands, a brand-new, breakthrough treatment expected to barrel past the blockbuster barrier almost immediately--and hit up to $7 billion in sales this year.
Merck's sales continue to get whacked by the loss of patent protection for its asthma blockbuster Singulair, but it managed to pull out fourth-quarter earnings that only barely missed Wall Street expectations, avoiding the "mega-miss" some analysts were braced for.
GlaxoSmithKline released its 2013 earnings report today, and made it abundantly clear that five new drug approvals in 2013 helped cushion the impact of increasing competition on older products and a bribery scandal in China.
A couple of weeks back, the Street was abuzz that Merck would hand over its consumer-health business for Novartis' animal-health and vaccines units. Yesterday, word was that Merck has some consumer-goods giants shopping its consumer-health aisle.
The tax advantages of doing business in Ireland have been plumbed by a number of drugmakers, some of whom have moved their homes there to cut taxes, and so costs. Alexion, maker of orphan drug Soliris, is bagging some of that benefit by expanding operations there.
India's Lupin is staking a claim in sterile injectables, with a deal to buy the Netherlands-based drugmaker Nanomi.
Advair's throne is slowly eroding. With stepped-up competition from rival lung drugs--including AstraZeneca's Symbicort--GlaxoSmithKline's top-selling product, with $7.7 billion in 2012 sales, is losing share in the U.S.
U.K. patients will get the chance to use three new Big Pharma cancer treatments. Unless and until Britain's cost watchdogs decide to back them for regular National Health Service use, the drugs will be reimbursed from a special fund for cancer drugs.
Indian drugmakers have a shot at bringing Gilead Sciences' hot new hepatitis C drug to their country. The California-based company is in talks with "a handful" of Indian pharmas to take Sovaldi to that country and other developing nations at a fraction of the U.S. price.
The National Institute for Health and Care Excellence, Britain's drug-review agency, is no longer recommending that Roche's targeted lung cancer drug Tarceva be used as a second-line treatment in patients with non-small cell lung cancer who have relapsed—sparking an angry response from the Swiss drugmaker.
Biogen Idec's fast-selling new multiple sclerosis drug won approval in a broad new market: Europe. After sewing up its Tecfidera intellectual property rights there last year, Biogen can now roll out the drug for first-line MS treatment across the continent.
Valeant Pharmaceuticals has snapped up another dermatology specialist in its ongoing quest to build its business in the field. This time, it's PreCision Dermatology, a Cumberland, RI-based maker of prescription skin remedies and skin-care products sold by physicians.